Gynecologic oncology最新文献

{"title":"EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol","authors":"Eef van den Borst ,&nbsp;Davy Vanden Broeck ,&nbsp;Philippe De Sutter ,&nbsp;Gilbert Donders ,&nbsp;Jean Doyen ,&nbsp;Wiebren Tjalma ,&nbsp;Steven Weyers ,&nbsp;Marc Arbyn ,&nbsp;Severien Van Keer ,&nbsp;Ardashel Latsuzbaia","doi":"10.1016/j.ygyno.2025.08.018","DOIUrl":"10.1016/j.ygyno.2025.08.018","url":null,"abstract":"<div><h3>Objective</h3><div>Human papillomavirus (HPV) testing on self-collected urine and vaginal samples has shown great potential for cervical cancer screening by offering a non-invasive and approachable alternative to un(<em>der</em>)screened populations. Although many HPV tests were validated on cervical samples, data regarding clinical performance on self-samples is warranted prior to its clinical use.</div></div><div><h3>Methods</h3><div>The VALHUDES framework was designed to evaluate the accuracy of HPV tests on self-samples. As such, five colposcopy clinics enrolled patients with aberrant cervical results, asking them to collect a first-void urine (Colli-Pee) and a vaginal self-sample (Evalyn Brush or Qvintip). Additionally, a clinician-collected cervical sample was collected as comparator. 0.4 mL of all samples was used for DNA extraction with Abbott <em>m2000,</em> eluting in 50 μL. To detect high-risk HPV, PCR was conducted on 5 μL DNA extract from all samples with the EUROArray HPV test. Disease outcome was determined by colposcopy with or without biopsy. Relative accuracy was estimated for each self-sample type compared to the clinician-collected sample.</div></div><div><h3>Results</h3><div>Data was available from 491 and 494 matched samples for vaginal and first-void urine self-samples, respectively. Relative sensitivity for CIN2+ was 0.96 (95 % CI: 0.91–1.02) for vaginal self-samples and 0.96 (95 % CI: 0.90–1.05) for first-void urine. The specificity for &lt;CIN2 was also not significantly lower on the self-samples compared to clinician-taken samples (relative specificity: 0.98 [95 % CI: 0.91–1.07] for vaginal self-samples and 0.94 [95 % CI: 0.85–1.04] for first-void urine).</div></div><div><h3>Conclusions</h3><div>The accuracy of EUROArray HPV is similar on vaginal self-samples and first-void urine compared to clinician-collected cervical samples.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"202 ","pages":"Pages 14-23"},"PeriodicalIF":4.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician variation in adopting opportunistic salpingectomy at the time of postpartum and interval sterilization for ovarian cancer risk reduction","authors":"Katherine Yoh ,&nbsp;Vrunda B. Desai ,&nbsp;Cary P. Gross ,&nbsp;Erica S. Spatz ,&nbsp;Craig Evan Pollack ,&nbsp;Jason D. Wright ,&nbsp;Xiao Xu","doi":"10.1016/j.ygyno.2025.08.033","DOIUrl":"10.1016/j.ygyno.2025.08.033","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine variation in physician adoption of opportunistic salpingectomy (OS) for patients undergoing tubal sterilization.</div></div><div><h3>Study design</h3><div>Using the Premier Healthcare Database, we identified patients age 18–49 undergoing postpartum or interval sterilization between January 2011–June 2022. Risk-adjusted rate of OS was estimated for each physician-year. Subsequently, we used group-based trajectory models to identify latent groups of physicians following distinct patterns of uptake and examined factors associated with the distinct trajectory patterns.</div></div><div><h3>Results</h3><div>Among 383,338 <em>postpartum sterilizations</em> (7550 physicians), OS increased from 0.1 % in 2011 to 14.3 % in 2022. Two physician adoption trajectories emerged: low (81.9 % of physicians; rate of OS: 0.049 % in 2011 and 6.1 % in 2022) and high (18.1 % of physicians; rate of OS: 0.02 % in 2011 and 55.3 % in 2022) adoption. Likewise, among 136,965 <em>interval sterilizations</em> (3401 physicians), OS rose from 1.4 % in 2011 to 65.9 % in 2022 with nearly equal number of physicians in the low (50.1 %; rate of OS: 0.6 % in 2011 and 25.7 % in 2022) and high (49.9 %; rate of OS: 0.6 % in 2011 and 95.8 % in 2022) adoption groups. Physicians with these distinct trajectories differed significantly in rural/urban location, geographic region, surgical volume, and patient composition. In particular, a 10-percentage-point increase in the proportion of Black patients was associated with lower odds of high adoption for both postpartum (aOR: 0.89, 95 % CI: 0.82–0.96) and interval (aOR: 0.89, 95 % CI: 0.84–0.94) sterilization.</div></div><div><h3>Conclusions</h3><div>While OS increased over time, a substantial proportion of physicians remained low adopters. Geographic and demographic differences in adoption suggest potential inequitable access.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"202 ","pages":"Pages 1-13"},"PeriodicalIF":4.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study","authors":"Mikko Loukovaara ,&nbsp;Annukka Pasanen ,&nbsp;Ralf Bützow","doi":"10.1016/j.ygyno.2025.08.031","DOIUrl":"10.1016/j.ygyno.2025.08.031","url":null,"abstract":"<div><h3>Objective</h3><div>This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (<em>POLE</em>) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.</div></div><div><h3>Results</h3><div>We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.2 %) experienced relapse (median follow-up: 65 months). The no specific molecular profile (NSMP) subgroup (<em>n</em> = 60) showed longer time to progression than the mismatch repair deficient (MMRd, <em>n</em> = 95; <em>P</em> = 0.047) and p53-abnormal (p53abn, <em>n</em> = 63; <em>P</em> = 0.009) subgroups. Only 2 <em>POLE</em> ultramutated tumors were present, precluding meaningful comparisons. In the NSMP subgroup, chemotherapy ± radiotherapy was associated with a longer time to progression compared to no adjuvant therapy (hazard ratio 0.13, 95 % confidence interval 0.044–0.37; <em>P</em> &lt; 0.001). Patterns of relapse suggested a tendency toward local relapses in NSMP, regional in MMRd, and distant in p53abn (<em>P</em> = 0.002). Pairwise comparisons of post-recurrence disease-specific survival indicated longer survival for NSMP than for MMRd (<em>P</em> = 0.014) or p53abn (<em>P</em> &lt; 0.001). Within NSMP, post-recurrence disease-specific survival was poorer for high-grade tumors, irrespective of estrogen receptor status, than low-grade tumors, all estrogen receptor-positive. PD-L1 expression was not associated with progression-free or disease-specific survival in molecular subgroup-specific analyses; however, PD-L1 positivity correlated with poorer post-recurrence disease-specific survival in MMRd tumors (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Our findings support the clinical utility of molecular classification in relapsed endometrial carcinoma and underscore the need to consider both molecular subtype and disease phase when assessing immune-related biomarkers.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"201 ","pages":"Pages 216-222"},"PeriodicalIF":4.1,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center","authors":"Sarah A. Ackroyd ,&nbsp;Gabrielle Sudilovsky ,&nbsp;Yan Che ,&nbsp;Austin Wesevich ,&nbsp;Sandra Tilmon ,&nbsp;Nita K. Lee ,&nbsp;S. Diane Yamada ,&nbsp;Gini F. Fleming","doi":"10.1016/j.ygyno.2025.08.025","DOIUrl":"10.1016/j.ygyno.2025.08.025","url":null,"abstract":"<div><h3>Objective</h3><div>To identify associations between race, neighborhood disadvantage, and outcomes in women with stage I-III endometrioid endometrial cancer (EEC) treated at a tertiary referral center.</div></div><div><h3>Methods</h3><div>This retrospective tumor registry study included patients with stage I-III EEC between 1/2006 and 12/2022. Progression-free (PFS) and overall survival (OS) were analyzed by race and neighborhood disadvantage, stratified by Area Deprivation Index (ADI; national quartile).</div></div><div><h3>Results</h3><div>Of 797 patients included, 112 (14 %) resided in the least disadvantaged quartile, 267 (34 %) in the second ADI quartile, 248 (31 %) in the third ADI quartile, and 170 (21 %) in the most disadvantaged quartile. A greater proportion of Black than White patients lived in the most disadvantaged areas (39 % vs 16 %, <em>p</em> &lt; 0.01). In adjusted Cox-proportion model for PFS, older age, higher grade, higher stage and living in the least disadvantaged areas were associated with a higher risk of progression, however, in adjusted model for OS, only higher stage and older age were associated with a higher risk of death. Race was not associated with PFS or OS.</div></div><div><h3>Conclusions</h3><div>In women with Stage I-III EEC treated at a single tertiary referral center, we did not find differences in outcomes when analyzed by ADI or race. Given previously reported racial disparities in outcomes for women with EEC, our data may reflect increased resources available to patients with access to a tertiary center regardless of residence. Future studies should focus on broader geographic areas and more individual measurements of vulnerability.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"201 ","pages":"Pages 203-209"},"PeriodicalIF":4.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis","authors":"Caterina FULGIONE ,&nbsp;Frediano INZANI ,&nbsp;Antonio RAFFONE ,&nbsp;Diego RAIMONDO ,&nbsp;Damiano ARCIUOLO ,&nbsp;Susanna RONCHI ,&nbsp;Deborah MARCHIORI ,&nbsp;Roberta MARAGLIANO ,&nbsp;Daniele NEOLA ,&nbsp;Maria Giovanna VASTARELLA ,&nbsp;Luigi COBELLIS ,&nbsp;Stefano L.A. ROSA ,&nbsp;Gian Franco ZANNONI ,&nbsp;Antonio TRAVAGLINO","doi":"10.1016/j.ygyno.2025.08.028","DOIUrl":"10.1016/j.ygyno.2025.08.028","url":null,"abstract":"<div><h3>Background</h3><div>Vulvar squamous cell carcinoma (VSCC) is subdivided into <em>TP53</em>-mutant (<em>TP53</em>^mut) and HPV-associated (HPV⁺). In recent years, a third group unrelated to <em>TP53</em> mutation or HPV-association (<em>TP53</em>^wt/HPV⁻) has emerged. However, its prognosis is unclear.</div></div><div><h3>Objective</h3><div>The aim of this study was to define the prognosis of <em>TP53</em>^wt/HPV⁻VSCC through a systematic review and meta-analysis.</div></div><div><h3>Methods</h3><div>Electronic databases were searched from their inception to February 2025 for studies comparing the prognosis of <em>TP53</em>^wt/HPV⁻ VSCC to that of <em>TP53</em>^mut and HPV⁺ VSCC. Pooled hazard ratios (HR) for recurrence-free survival (RFS) and disease-specific survival (DSS) were calculated, with a significant <em>p</em>-value&lt;0.05.</div></div><div><h3>Results</h3><div>Six studies were included in the systematic review, while 5 studies with 1355 VSCCs (755 <em>TP53</em>^mut, 302 HPV⁺, 298 <em>TP53</em>^wt/HPV⁻) were included in the meta-analysis. <em>TP53</em>^wt/HPV⁻ VSCC showed significantly better PFS (HR = 0.714; <em>p</em> = 0.022) and DSS (HR = 0.633; <em>p</em> = 0.037) than <em>TP53</em>^mut VSCC and significantly worse PFS (HR = 2.555; <em>p</em> = 0.001) and DSS (HR = 1.973; <em>p</em> = 0.024) than HPV⁺ VSCC.</div></div><div><h3>Conclusions</h3><div><em>TP53</em>^wt/HPV⁻ VSCCs constitute a group at intermediate risk, with a prognosis significantly better than <em>TP53</em>^mut VSCC and significantly worse than HPV⁺ VSCC.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"201 ","pages":"Pages 210-215"},"PeriodicalIF":4.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol","authors":"Koji Matsuo ,&nbsp;Danielle M. Enserro ,&nbsp;Jason D. Wright ,&nbsp;Lynda D. Roman ,&nbsp;Matthew A. Powell ,&nbsp;David S. Miller ,&nbsp;Christa I. Nagel ,&nbsp;Premal H. Thaker ,&nbsp;Robert S. Mannel ,&nbsp;Ashley R. Stuckey ,&nbsp;Saketh R. Guntupalli ,&nbsp;Paniti Sukumvanich ,&nbsp;Melissa A. Geller ,&nbsp;Roberto Vargas ,&nbsp;Gottfried E. Konecny ,&nbsp;David P. Warshal ,&nbsp;Krishnansu S. Tewari ,&nbsp;Nick M. Spirtos ,&nbsp;Bhavana Pothuri ,&nbsp;William T. Creasman ,&nbsp;David G. Mutch","doi":"10.1016/j.ygyno.2025.08.029","DOIUrl":"10.1016/j.ygyno.2025.08.029","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the association between malignant peritoneal cytology and survival outcomes in endometrial cancer.</div></div><div><h3>Methods</h3><div>This was an ancillary analysis of prospectively collected surgical-pathological data in the NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. The study population included 2383 patients with stage I-III endometrial cancer from 2003 to 2011. Exposure was peritoneal cytology status: malignant peritoneal cytology (<em>n</em> = 215) or negative peritoneal cytology (<em>n</em> = 2168). Main outcome measures were recurrence-free survival and overall survival. Propensity score inverse probability treatment weighting was performed to balance the baseline clinico-pathological characteristics, followed by adjustment for adjuvant therapy.</div></div><div><h3>Results</h3><div>Malignant peritoneal cytology was associated with a 32% increased risk of recurrence (5-year rates, 72% versus 77%, hazard ratio 1.32, 95% confidence interval 1.03 to 1.69, <em>P</em> = 0.028) and 37% increased risk of all-cause mortality (78% versus 83%, hazard ratio 1.37, 95% confidence interval 1.06 to 1.78, <em>P</em> = 0.018) compared to negative peritoneal cytology. When controlling for adjuvant therapy, the association between malignant peritoneal cytology and survival was attenuated for both recurrence-free survival (adjusted-hazard ratio 1.16, 95% confidence interval 0.90 to 1.50, <em>P</em> = 0.24) and overall survival (adjusted-hazard ratio 1.22, 95% confidence interval 0.93 to 1.60, <em>P</em> = 0.16) without statistical significance. Peritoneal cytology status and adjuvant therapy type had a possible interaction on overall survival, and malignant peritoneal cytology was associated with decreased overall survival when radiotherapy was received as adjuvant therapy but not when chemotherapy was utilized (<em>P-interaction</em> = 0.059).</div></div><div><h3>Conclusion</h3><div>The results of this prospective assessment suggest that malignant peritoneal cytology is a prognostic factor, if any, associated with a modest decrease in survival for endometrial cancer.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"201 ","pages":"Pages 184-194"},"PeriodicalIF":4.1,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts","authors":"Victoria M. Ettorre ,&nbsp;Cem Demirkiran ,&nbsp;Stefania Bellone ,&nbsp;Tobias Max Philipp Hartwich ,&nbsp;Michelle Greenman ,&nbsp;Blair McNamara ,&nbsp;Namrata Sethi ,&nbsp;Luca Palmieri ,&nbsp;Alessandro D. Santin","doi":"10.1016/j.ygyno.2025.08.027","DOIUrl":"10.1016/j.ygyno.2025.08.027","url":null,"abstract":"<div><h3>Background</h3><div>Cervical cancer is one of the most prevalent and deadly cancers worldwide. Here we demonstrate the preclinical pharmacology of Dato-DXd, a TROP2-targeting antibody-drug conjugate (ADC), against primary cervical cancer cell lines and xenografts.</div></div><div><h3>Methods</h3><div>Primary cervical cancer cell lines with differential TROP2 expression were identified by flow cytometry. Tumor cell death was evaluated at serial dilutions of Dato-DXd in TROP2-expressing and non-expressing cell lines. CSFE-incubated lines were evaluated for the ability of Dato-DXd to induce bystander killing after admixing TROP2-expressing tumor cells with non-expressing tumor cells. Dato-DXd-induced apoptosis was evaluated using phosphorylated H2AX. Antibody-directed cellular cytotoxicity (ADCC) was evaluated using a standard 4-h ⁵¹Cr assay. Finally, the in vivo anti-tumor activity of Dato-DXd was assessed in TROP2-expressing cervical cancer mouse models.</div></div><div><h3>Results</h3><div>67 % (4/6) of primary cervical cancer cell lines showed high expression of TROP2. Dato-DXd was highly effective in inducing tumor cell death in TROP2-expressing cell lines (CVX4 and CVX8) while no killing was induced against TROP2 non-expressing cell lines (ADX2). When TROP2+ tumor cells (CVX4) were co-cultured with TROP2 negative tumor cells (ADX2) in the presence of Dato-DXd, significant bystander activity was noted against ADX2 cells. Dato-DXd exposure increased phosphorylated H2AX, a marker of apoptosis, and induced significant levels of ADCC in TROP2-expressing models. In vivo, Dato-DXd was effective in tumor growth suppression and the median overall survival was unreached by day 50 in mice harboring TROP2+ xenografts.</div></div><div><h3>Conclusion</h3><div>Dato-DXd demonstrated remarkable preclinical activity against TROP2-expressing primary cervical cancer cell lines and xenografts. Clinical evaluation of Dato-DXd is warranted in advanced/recurrent cervical cancer patients.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"201 ","pages":"Pages 195-202"},"PeriodicalIF":4.1,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel anatomical concept and standardized technique for single-port Paraaortic lymphadenectomy in gynecological cancers","authors":"Zejian Lin ,&nbsp;Zhimin Liu ,&nbsp;Jieping Chen ,&nbsp;Haifeng Gu,&nbsp;Guochen Liu,&nbsp;Jihong Liu,&nbsp;Hua Tu","doi":"10.1016/j.ygyno.2025.08.026","DOIUrl":"10.1016/j.ygyno.2025.08.026","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the feasibility, safety, and quality of a standardized technique for single-port laparoscopic paraaortic lymphadenectomy guided by a novel anatomical concept.</div></div><div><h3>Methods</h3><div>This single-center prospective study enrolled patients with gynecological cancers requiring paraaortic lymphadenectomy from February 2022 to May 2025. All patients underwent single-port laparoscopic paraaortic lymphadenectomy using a standardized technique grounded in a novel “renal vein angle” anatomical concept. Primary endpoints assessed technical feasibility (completion rate), safety (intra/postoperative complications, blood loss), and quality (paraaortic lymphadenectomy to renal vein level, operative time, lymph node yield). All procedures were video-documented in high-definition or captured via time-stamped photographic key steps.</div></div><div><h3>Results</h3><div>Sixty consecutive patients underwent single-port laparoscopic paraaortic lymphadenectomy, including 52 with endometrial cancer, seven with ovarian cancer, and one with cervical cancer. The median patient age was 54 years, and the median BMI was 25.6 kg/m². The standardized technique achieved a 100 % completion rate with 100 % skeletonization of the left renal vein, inferior vena cava, and aorta. The median number of dissected para-aortic lymph nodes was 21 (range 11–37). The median operative duration was 95 min (range 53–285), and the median blood loss was 30 mL (range 5–150). No major complications, conversions to laparotomy, or additional trocar placement were observed. Ten patients had nodal metastases on postoperative pathological examination. No recurrence or delayed complications were observed after a median follow-up period of 15 months (range 0–38).</div></div><div><h3>Conclusion</h3><div>The standardized technique guided by novel anatomical concept demonstrated sufficient feasibility, safety, and quality for single-port laparoscopic paraaortic lymphadenectomy.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"201 ","pages":"Pages 176-183"},"PeriodicalIF":4.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rural perspectives in endometrial cancer: A qualitative evaluation","authors":"Ashlee Candelaria ,&nbsp;Colleen McCormick ,&nbsp;Heidi Rishel Brakey ,&nbsp;Maria Juarez Parra ,&nbsp;Stephanie Rieder","doi":"10.1016/j.ygyno.2025.04.555","DOIUrl":"10.1016/j.ygyno.2025.04.555","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"200 ","pages":"Pages S23-S24"},"PeriodicalIF":4.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equity starts with prevention: Sociodemographic variables as predictors to access for hereditary cancer prevention care","authors":"Maya Gross,&nbsp;Kemi Doll,&nbsp;Soledad Jorge,&nbsp;Barbara Norquist","doi":"10.1016/j.ygyno.2025.04.536","DOIUrl":"10.1016/j.ygyno.2025.04.536","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"200 ","pages":"Page S11"},"PeriodicalIF":4.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}